Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Urology

Journal Scan / Research · July 25, 2018

PSA Density as a Predictor of Significant Prostate Cancer: Defining the Optimum Cut-Point Stratified by Race and BMI

The Journal of Urology


Additional Info

The Journal of Urology
Prostate-Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the PSA Level Is in the Diagnostic "Grey-Zone": Defining the Optimum Cut-Point Stratified by Race and Body Mass Index
J Urol 2018 May 11;[EPub Ahead of Print], A Aminsharifi, L Howard, Y Wu, A De Hoedt, C Bailey, SJ Freedland, TJ Polascik

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading